Integrating Chinese and western medicine for COVID-19: A living evidence-based guideline (version 1).
Long GeHongfei ZhuQi WangMengting LiJianxiong CaiYang ChenYaolong ChenBanghan DingBangjiang FangYutong FeiJihong FengXinfeng GuoRongmeng JiangYuyong JiangGuiwei LiXiuhui LiXucheng LiQun LiangJian LiuJianping LiuQingquan LiuShaonan LiuYun LuQing MiaoWensheng QiHongcai ShangLiqing ShiXingHua TanXudong TangXianbo WangXiaojun WangWenguang XiaKehu YangLihong YangYongan YeQi ZhouHongchun ZhangJunhua ZhangZhiming ZhangZhongde ZhangXu ZouJun LiDarong WuPublished in: Journal of evidence-based medicine (2021)
This guideline panel made nine recommendations, which covered five traditional Chinese medicine (TCM) prescription granules/decoction (MXXFJD, QFPD, XFBD, TJQW, and JWDY), three Chinese patent medicines (LHQW granules/capsule, JHQG granules, and LHQK granules), and one Chinese herbal injection (XBJ injection). Of them, two were strongly recommended (LHQW granules/capsule and QFPD decoction), and five were weakly recommended (MXXFJD decoction, XFBD decoction, JHQG granules, TJQW granules, and JWDY decoction) for the treatment of mild and moderate COVID-19; two were weakly recommended against (XBJ injection and LHQK granules) the treatment of mild and moderate COVID-19. The users of this living guideline are most likely to be clinicians, patients, governments, ministries, and health administrators.